Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-04-18 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
董事会秘书工作细则（2025年4月修订）
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作细则' which translates to 'Board Secretary Work Rules' or 'Board Secretary Procedures'. It details the duties, qualifications, appointment, and legal responsibilities of the company's board secretary. It references relevant laws and regulations, outlines internal governance procedures, and specifies the role of the board secretary in corporate governance and compliance. There is no financial data, no report of financial results, no announcement of voting results, no audit information, no earnings release, no capital or financing update, no legal proceedings update, no merger or acquisition activity, and no other report or announcement type that fits the other categories. This document is a governance-related internal rules document describing the company's governance practices and board secretary responsibilities. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4323 characters, which is sufficient for a detailed governance document, and it is not a short announcement or certification. Confidence is high due to the clear content and purpose of the document.
2025-04-18 Chinese
总经理工作细则（2025年4月修订）
Governance Information Classification · 95% confidence The document is titled '总经理工作细则' which translates to 'General Manager Work Rules' or 'General Manager Operating Procedures'. It details the roles, responsibilities, qualifications, and authority of the company's general manager, deputy general managers, and financial director. It also outlines the structure and governance of the management team, meeting procedures, and accountability measures. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no legal proceedings, no capital changes, or any other typical financial or regulatory report content. The document is a governance-related internal policy document focusing on management roles and governance practices. Therefore, it fits best under Governance Information (CGR). The document length is 4202 characters, which is sufficient for a detailed governance report rather than a brief announcement or notice.
2025-04-18 Chinese
第四届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Lingkang Pharmaceutical Group Co., Ltd. It details the outcomes of the 17th meeting of the 4th Supervisory Board, including approvals of various reports such as the 2024 Supervisory Board Work Report, the 2024 Annual Report, the 2024 Financial Final Accounts Report, the 2024 Profit Distribution Plan, and other related proposals. The document is a formal announcement of meeting resolutions and approvals, not the reports themselves. It also mentions that these items will be submitted to the 2024 Annual General Meeting for approval. The document length is short (1479 characters) and it serves as an official announcement of meeting decisions rather than containing the full reports or detailed financial data. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement of board meeting resolutions and approvals, rather than the Annual Report (10-K) or Management Reports (MDA).
2025-04-18 Chinese
第四届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of Lingkang Pharmaceutical Group Co., Ltd. It includes approvals of various reports such as the 2024 General Manager Work Report, 2024 Board Work Report, 2024 Annual Report full text and summary, 2024 Financial Final Accounts Report, 2024 Profit Distribution Plan, and other related reports. The document also mentions that these reports will be submitted to the 2024 Annual General Meeting for approval. The document is not the actual annual report or financial statements but a board meeting resolution announcement regarding these reports. It also includes procedural details about the meeting and voting results. The document length is 2513 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces board meeting decisions and management reports approvals, not the reports themselves.
2025-04-18 Chinese
2024年年度审计报告
Regulatory Filings
2025-04-18 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "灵康药业集团股份有限公司 2024 年年度报告" which translates to "Lingkang Pharmaceutical Group Co., Ltd. 2024 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, industry and market position, and audited financial statements. The document includes signatures from the board and auditors, and covers the full fiscal year 2024. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data, management analysis, and audit opinions confirms this is the official annual report of the company for the year 2024. FY 2024
2025-04-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.